Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|October 2, 2004
- Pharmaceutical Technology-10-02-2004
- Volume 28
- Issue 10
October 2004
Author(s)Pharmaceutical Technology Editors
Pharmaceutical Science & Technology News
Advertisement
Articles in this issue
almost 22 years ago
A Novel Freeze Pelletization Technique for Preparing Matix Pelletsalmost 22 years ago
Aseptic Processing: A Review of Current Industry Practicealmost 22 years ago
Can Inserts Be Improved?almost 22 years ago
Drug Development Linked More Closely to Diagnosticsalmost 22 years ago
In The Spotlight-October 2004almost 22 years ago
The High Price of Successalmost 22 years ago
Pharma Company Investment in Parenteral Manufacturing Capacity Picking UpAdvertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
3
PharmTech’s Weekly Roundup—September 25, 2026
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5